Clinical and pathomorphological analysis of deaths from COVID-19 in 2020

O. V. Riabokon1, A. C. F., L. M. Tumanska1, B. C., V. V. Cherkaskyi1, D. B. C., Yu. Yu. Riabokon1, D. E.

Clinic and pathomorphological analysis of deaths from COVID-19 in 2020.

Materials and methods. We analyzed 41 case histories and results of pathological-anatomical examination of patients who died of COVID-19 during 2020.

Results. The lethal outcome of COVID-19 disease was recorded at day 22 (16; 27) of the disease. Among the dead, there is a high percentage of men (73.2 %), early old age and middle old age patients (75.6 %) with comorbid pathology (92.7 %). Early lung damage with COVID-19 in the deceased was determined by pronounced interstitial and interstitial-alveolar edema, the presence of erythrocyte stasis in the pulmonary microvessels, blood clots and hypoperfusion leukocyte stasis, as well as the presence of erythrocytes in the alveoli. Bilateral polynuclear subcutaneous viral pneumonia in 90.2 % of dead patients was characterized by significant edema and thickening of the alveolar walls with their moderate infiltration by lymphocytes, focal peribronchial and perivascular inflammatory polymorphonuclear infiltration, multiple and small exfoliated alveolar epithelium (87.8 %), as well as metaplasia of a few alveolocytes preserved on the luminal surface of the alveoli (82.9 %). Every tenth person who died of COVID-19 had signs of secondary bacterial microflora. In 85.4 % of patients who died on day 22–27 of the disease focal or sublobar pneumofibrosis was diagnosed. In those who died due to COVID-19, multiorgan failure was characterized by focal necrosis of the renal tubular epithelium (73.2 %), focal lymphocytic-leukocyte infiltration (12.2 %) and renal microvascular thrombosis (17.1 %), focal centrolobular necrosis (90.2 %) and focal lymphocytic-leukocyte infiltration of lobes (7.3 %) of the liver. Thrombotic complications were confirmed in 22.0 % of deceased patients: ischemic cerebral infarction, transmural myocardial infarction, pulmonary embolism, deep vein thrombosis of the lower extremities under the pathology. These thrombotic complications were not diagnosed in all patients during life. The majority of deaths due to COVID-19 had morphological signs of chronic cardiovascular pathology. Ischemic heart disease and hypertension during the life of patients were diagnosed in all cases.

Conclusions. Early lung damage in COVID-19 in the deceased was determined by pronounced interstitial-alveolar edema, blood clots and leukocyte stasis in microvessels, less often – the presence of “hyaline membranes”. In 90.2 % of dead patients bilateral polynuclear subcutaneous viral pneumonia with edema and lymphocytic infiltration of the pulmonary interstitium, inflammatory peribronchial and perivascular focal polymorphonuclear infiltrates, foci of atelectasis and dyscrasias was found. In 9.7 % of patients bilateral subcutaneous viral-bacterial fibrinous-purulent bronchopneumonia developed. In those who died on the 22nd–27th day of the disease focal pneumofibrosis was determined. Pathomorphologically, thrombotic complications, which were not diagnosed in all patients during their lifetime, were confirmed in 22.0 % of deceased patients. Most deaths from COVID-19 had morphological signs of chronic cardiovascular disease.
Цель работы — провести клинико-патоморфологический анализ летальных случаев от коронавирусной болезни (COVID-19) в 2020 году.

Материалы и методы. Проанализированы 41 историю болезни и результаты патологоанатомического исследования пациентов, умерших вследствие COVID-19 в 2020 году.

Результаты. Летальный исход вследствие COVID-19 зафиксирован на 22 (16; 27) сутки болезни с преобладанием среди заболевших мужчин (73,2 %), пациентов пожилого и старческого возраста (75,6 %) с наличием коморбидной патологии (92,7 %). Раннее поражение лёгких при COVID-19 у умерших проявлялось выраженным интерстициальным и интерстициально-альвеолярным отёком, а также наличием в микрососудах лёгких стаза эритроцитов, микросгустков крови и гипоперфузионных лейкоцитарных стазов, а также наличием в альвеолах эритроцитов, гемосидерофагов, макрофагов, дисплазически измененного альвеолярного эпителия. У 9,7 % умерших в микрососудах лёгких наблюдалась значительный отёк и утолщение стенок альвеол, наличие гиалиновых мембран. Двусторонняя полисегментарная субтотальная вирусно-бактериальная фибринозно-гнойная бронхопневмония у 85,4 % умерших на 22–27 сутки болезни включала в себя характеристики множественных инфарктов лёгких разной давности, тромбоз глубоких вен верхней конечности.

У большинства умерших вследствие COVID-19 в 2020 году отмечены морфологические признаки хронической сердечно-сосудистой патологии. Ишемическая болезнь сердца и гипертоническая болезнь при жизни пациентов диагностированы не во всех случаях. Умерших в 2020 году с кардиоваскулярными заболеваниями в 22,0 % от общего количества умерших выявлены морфологические ознаки хронической сердечно-сосудистой патологии.

Выводы. Раннее поражение лёгких при COVID-19 у умерших определялось выраженным интерстициально-альвеолярным отёком, микросгустками крови и лейкоцитарными стазами в микрососудах, реже — наличием гиалиновых мембран. У 90,2 % умерших пациентов выявлены дебютная полисегментарная субтотальная вирусная пневмония с выраженным отёком и утолщением стенок альвеол, наличием в альвеолах эритроцитов, гемосидерофагов, макрофагов, дисплазически измененного альвеолярного эпителия.

Раннее поражение лёгких при COVID-19 у умерших определялось выраженным интерстициально-альвеолярным отёком, микросгустками крови и лейкоцитарными стазами в микрососудах, реже — наличием гиалиновых мембран. У 90,2 % умерших пациентов выявлены дебютная полисегментарная субтотальная вирусная пневмония с выраженным отёком и утолщением стенок альвеол, наличием в альвеолах эритроцитов, гемосидерофагов, макрофагов, дисплазически измененного альвеолярного эпителия. У 9,7 % умерших в микрососудах лёгких наблюдалась значительный отёк и утолщение стенок альвеол, наличие гиалиновых мембран. Двусторонняя полисегментарная субтотальная вирусно-бактериальная фибринозно-гнойная бронхопневмония у 85,4 % умерших на 22–27 сутки болезни включала в себя характеристики множественных инфарктов лёгких разной давности, тромбоз глубоких вен верхней конечности.

У большинства умерших вследствие COVID-19 в 2020 году отмечены морфологические признаки хронической сердечно-сосудистой патологии.
Under the conditions of pandemic spread of coronavirus SARS-CoV-2, every fifth patient develops a severe course of the disease with a high risk of death [1]. Even in the presence of modern diagnostic tests, pathomorphological examination of deaths during the pandemic of the new coronavirus COVID-19 is of particular importance and can significantly affect the understanding of the disease pathogenesis. The data obtained may have an impact on the therapeutic strategy for the treatment of a new infection [2].

It is known that ACE2 is a receptor that uses SARS-CoV and SARS-CoV-2 to penetrate the target cell [3,4]. At the tissue level, ACE2-receptors are highly expressed in the lungs, kidneys, heart, and vascular endothelium, which may explain the presence of multiorgan lesions in patients with SARS-CoV and SARS-CoV-2 coronavirus [5,6]. The appearance of multiorgan lesions can be explained by the development of “cytokine storm” in conditions of severe and critical course of the disease. “Cytokine storm” can be a manifestation of a hyperimmune response with hyperproduction of proinflammatory cytokines and chemokines by immune cells and the development of systemic endotheliitis with hypercoagulation [7,8]. Despite the fact that in the pandemic of highly contagious COVID-19 pathomorphological studies are somewhat limited, the accumulation of results of these studies continues [9–12]. At the same time, the clinical and pathomorphological analysis of the obtained results is of special importance.

Aim

The aim of the work – to conduct clinical and pathomorphological analysis of deaths from COVID-19 in 2020.

Materials and methods

We analyzed 41 case histories and results of pathoanatomical examination of patients who were treated in the intensive care unit of the Municipal Non-Profit Enterprise “Regional infectious diseases clinical hospital” of Zaporizhzhia Regional Council and died of coronavirus COVID-19 during 2020. Pathoanatomical examination was performed in Municipal Institution “Zaporizhzhia Regional Bureau of Forensic Medical Examination” of Zaporizhzhia Regional Council.

Age of the dead was from 48 to 85 years. There were 30 men and 11 women. The diagnosis of COVID-19 in all cases was confirmed by the isolation of SARS-CoV-2 RNA in nasopharyngeal mucus or sputum. All patients were examined and treated in accordance with current regulations: Order of the Ministry of Health (MOH) of Ukraine dated 28.03.2020, No. 722 “Organization of medical care for patients with coronavirus disease (COVID-19)” (as amended by the order of the MOH of Ukraine dated 17.09.2020, No. 2122 “On amendments to the Standards of medical care of “Coronavirus disease (COVID-19)”); Order of the MOH of Ukraine No. 10 dated 07.01.2021 “On approval of Amendments to the Standards of medical care of “Coronavirus disease (COVID-19)”); Order of the MOH of Ukraine dated April 6, 2021 No. 638 “Protocol for the provision of medical care for the treatment of coronavirus disease (COVID-19)”.

Statistical data processing was performed in the program Statistica for Windows 13 (StatSoft Inc., license number JPZ8041382130ARCHN10-J).

Results

According to the results of the analysis, it was found that men predominated among those who died as a result of COVID-19 (n = 30, 73.2 %). More than half of the patients were early old aged (n = 23, 56.1 %), every fourth patient was middle adulthood (n = 10, 24.4 %), and every fifth was middle old aged (n = 8, 19.5 %).

Patients were hospitalized in an infectious hospital at day 9.0 [7.0; 12.0] of illness, and after deterioration – by day 8.5 [6.0; 11.0] of treatment in an outpatient setting. Deterioration was expressed by febrile (n = 26, 63.4 %) or subfebrile (n = 13, 31.7 %) fever, shortness of breath with a respiratory rate of 28.0 [28.0; 32.0] per minute, hemoptoysis (n = 4, 9.8 %), reducing oxygen saturation to 82.0 [75.0; 86.0] %, short-term diarrheal syndrome (n = 5, 12.2 %). At hospitalization, all patients had auscultatory signs (respiratory failure, crepitation) of bilateral pneumonia, which was confirmed radiologically, by computed tomography or lungs ultrasound with a lesion of 56.0 [51.0; 62.5] % of the lungs. The development of acute respiratory failure was accompanied by the appearance of acrocyanosis (n = 27, 65.9 %), and 2 (4.9 %) patients were taken to the intensive care unit (ICU) from other hospitals on artificial ventilation of the lungs (AVL).

Patients showed the following laboratory changes that characterized the severity of immune inflammation and hypercoagulation: leukocytosis in 29 (70.7 %) patients, the median of this indicator was 11.1 [7.9; 13.7] × 10^9/l; band neutrophils shift in 16 (39.0 %) with the presence of metamyelocytes in 2 (4.9 %) patients; development of absolute lymphopenia from 1.00 to 0.39 with a median of 0.8 [0.6; 1.1] × 10^9/l in the vast majority of patients (n = 35, 85.4 %); acceleration of ESR to 38.0 [25.0; 47.0] mm/h; increase in C-reactive protein in all patients to 150.5 [101.5; 235.5] ng/ml; increasing the level of interleukin-6 to 60.1 [25.0; 81.4] ng/ml; increasing the level of D-dimer to 1.4 [0.9; 9.4] mg/l; increase in C-reactive protein in all patients to 150.5 [101.5; 235.5] ng/ml; increasing the level of interleukin-6 to 60.1 [25.0; 81.4] ng/ml; hyperfibrinogenemia from 4.8 to 8.4 g/l in 32 (78.0 %) patients with a median of this indicator of 5.1 [4.3; 6.4] g/l; increasing the level of D-dimer to 1.4 [0.9; 9.4] mg/l and ferritin to 760.0 [482.0; 1148.0] ng/ml.

The duration of patients treatment in the ICU was from 2 to 38 days, the median was 11.0 [7.0; 18.0] days. During this period, patients received treatment according to the protocol of the MOH of Ukraine, every fifth patient (n = 8, 19.5 %) received tocilizumab. Despite the ongoing treatment, these patients progressed to respiratory failure, which required the transfer of patients to non-invasive ventilation or AVL. The median duration of AVL was 2.0 [1.0; 6.0] days. The dynamics increased the proportion of patients with signs of leukocytosis (n = 39, 95.1 %) with a median of this indicator of 16.2 [12.5; 24.2] × 10^9/l. It should be noted that every fourth patient (n = 11, 26.8 %) has hyperleukocytosis in the range from 20.3 to 54.4 × 10^9/l. The increase in endogenous intoxication and immune inflammation with hypercoagulation was evidenced by the preservation of absolute lymphopenia.
**Table 1. Pathomorphological changes in the lungs of patients who died of COVID-19, abs (%)**

| Pathomorphological sign                                                                 | Detection frequency (n = 41) |
|----------------------------------------------------------------------------------------|-----------------------------|
| Interstitial-alveolar pulmonary edema with the presence of erythrocyte stasis and blood clots in microvessels | 41 (100 %)                  |
| Bilateral polysegmental subtotal viral pneumonia:                                       |                             |
| – edema and thickening of the alveolus walls with moderate lymphocytic-lymphocyte infiltration; | 37 (90.2 %)                 |
| – focal peribronchial and perivascular inflammatory polymorphonuclear infiltration;     | 37 (90.2 %)                 |
| – multiple small foci of atelectases and dyslectases;                                   | 37 (90.2 %)                 |
| – the presence of erythrocytes, hemosiderophages, macrophages, squamous alveolar epithelium in the alveoli; | 36 (87.8 %)                 |
| – metaplasia of small alveolocytes on the luminal surface of the alveoli;               | 34 (82.9 %)                 |
| – presence of fibrin in some parietal layers alveoli ’ ’hyaline membranes’’;           | 15 (36.6 %)                 |
| – hypoperfusion leukocyte stasis in microvessels.                                       | 11 (26.8 %)                 |
| Interoveolar fibrosis, perivascular and peribronchial fibrosis                          | 35 (85.4 %)                 |
| Big-focal or sublobar pneumosclerosis                                                   | 35 (85.4 %)                 |
| Bilateral hydrothorax                                                                   | 9 (21.9 %)                  |
| Fibrosiurant purulent tracheobronchitis and bilateral subtotal viral-bacterial fibrous-purulent bronchopneumonia | 4 (9.7 %)                   |
| Bilateral fibrinous-purulent pleuritis                                                  | 3 (7.3 %)                   |

(n = 24, 58.5 %), band neutrophils shift (n = 10, 24.4 %), an increase in the proportion of patients with metamyelocytes (n = 17, 41.5 %), an increase of median D-dimer level up to 5.5 [1.6; 21.1] mg/ml. Despite treatment, hyperfibrinogenemia persisted (n = 28, 68.3 %), increasing the level of C-reactive protein to 127.0 [42.0; 221.0] mg/l and ferritin to 511.0 [360.0; 1314.0] ng/ml.

Fatal outcome of COVID-19 disease was recorded at day 22.0 [16.0; 27.0] of the disease. Pathomorphological signs of early lung damage in COVID-19 in the deceased were determined by pronounced interstitial and interalveolar edema, the presence in the pulmonary microvessels of erythrocytes stasis and blood clots and hypoperfusion leukocyte stasis, and erythrocytes in alveoli (Fig. 1, 2). The presence of fibrin in the alveoli of the parietal layers, the so-called “hyaline membranes” occurred in 36.6 % of deceased patients (Table 1).

The vast majority of patients (90.2 %) subsequently developed bilateral polysegmental subtotal viral pneumonia. According to pathomorphological data (Fig. 2, 3, 4), it was characterized by significant edema and thickening of the alveolar walls with their moderate predominantly lymphocytic infiltration (90.2 %), focal peribronchial and perivascular inflammatory polymorphonuclear infiltration (90.2 %), multiple small atelectases and dyslectases (90.2 %), the presence of erythrocytes clusters, hemosiderophages and macrophages, squamous alveolar epithelium in the alveoli (87.8 %), and metaplasia of a few alveolocytes preserved on the luminal surface of the alveoli (82.9 %). Bilateral subtotal viral-bacterial fibrinous-purulent bronchopneumonia (9.7 %) was detected in 4 deceased men during the pathomorphological examination of the lungs (Table 1). In these cases, treatment in the ICU lasted from 17 to 24 days. Patients received sequential oxygen therapy in a mask mode, then non-invasive lung ventilation and only during the last 1–2 days were transferred to ALV. In 35 (85.4 %) patients, who died on day 22–27 of the disease, there were fibrosis of the interalveolar septa, perivascular and peribronchial fibrosis (Fig. 5), big-focal or sublobar pneumosclerosis (Fig. 6).

One 54-year-old patient treated with a protocol using immunotrophic drugs (including tocilizumab, for the correction of clinical and laboratory manifestations of “cytokine storm”), antibacterial drugs and low molecular weight heparins, was diagnosed in the second week of the disease with sepsis (progression of respiratory failure, multiorgan failure syndrome, bacteriologically isolated from the blood Klebsiella pneumonia). The lethal outcome was recorded after three weeks of treatment. At pathoanatomical examination in the lung tissue, along with the presence of bilateral polysegmental subtotal hemorrhagic viral pneumonia signs, there was fibrinous-purulent pleurisy with pronounced inflammatory polymorphic-cellular infiltration of the layers of the parietal and visceral pleura, fibrinous-purulent tracheobronchitis. Foci of leukocyte-lymphocytic infiltration, as well as tubular necrosis of the kidneys and centrolobular necrosis of the liver were found in the tissue of the kidneys and liver. Morphological manifestations of sepsis were characterized by the presence of septic spleen: foci of red pulp myelosis, plasma-leukocyte infiltration, hemolysis of erythrocytes, hemosiderin sedimentation, foci of necrosis.

It should be noted that the unfavorable course of COVID-19 was facilitated by comorbid pathology, which was diagnosed in life in 38 (92.7 %) patients who died from COVID-19. Thus, the vast majority had cardiovascular comorbidities, namely coronary heart disease (80.5 %) with arrhythmias in the form of permanent atrial fibrillation (29.3 %) and hypertension (75.6 %). The presence of type 2 diabetes mellitus in almost half of patients (46.3 %) and grade II–III obesity in every third patient (31.7 %) is noteworthy. It should be noted that more than half of the COVID-19 patients who died had a combination of three or more comorbid conditions (Fig. 7).

Pathomorphological changes in other organs of those who died due to COVID-19 reflect multiorgan failure, which arose due to acute respiratory failure of III degree and endogenous intoxication. On the other hand, pathomorphological changes indicate the presence of a number of comorbid states. It should be noted that pathomorphological signs of comorbid cardiovascular pathology were found somewhat more often than was diagnosed in life. There was high frequency of pathomorphological signs detection of necrotic changes in the kidneys (73.2 %), liver (90.2 %), selective neuronal necrosis in the brain (19.5 %) (Table 2).

According to the results of pathoanatomical examination, 9 (22.0 %) deaths due to COVID-19 developed...
Fig. 1. Bilateral polysegmental pneumonia in COVID-19: significant swelling of the interlobular interstitium, lymphocyte-leukocyte exudate in the alveoli. Hematoxylin and eosin staining. Magnification: ×100.

Fig. 2. Bilateral polysegmental pneumonia in COVID-19: microvascular hyperemia and edema of the interalveolar septa, blood clots in the arterioles and venules, lymphocyte-leukocyte exudate and erythrocytes in the alveoli. Hematoxylin and eosin staining. Magnification: ×400.

Fig. 3. Bilateral polysegmental pneumonia with COVID-19: predominantly alveolar edema, alveolocyte metaplasia. Hematoxylin and eosin staining. Magnification: ×400.

Fig. 4. Bilateral polysegmental pneumonia in COVID-19: mainly lymphocytic infiltration of thickened interalveolar septa, desquamation of alveolocytes, erythrocytes in alveoli. Hematoxylin and eosin staining. Magnification: ×300.

Fig. 5. Interalveolar membranes fibrosis, desquamated alveolocytes and macrophages in alveoli in bilateral polysegmental COVID-19 pneumonia. Hematoxylin and eosin staining. Magnification: ×200.

Fig. 6. Focal pneumocerosis: erythrocytes, desquamated alveolocytes, macrophages and hemosiderophages in the alveoli in bilateral polysegmental COVID-19 pneumonia. Hematoxylin and eosin staining. Magnification: ×200.
They led to the development of ischemic heart attack (4 patients); transmural myocardial infarction (1 patient); myocardial infarction complicated by focal infarction-pneumonia due to pulmonary embolism of small vessels of the pulmonary artery (2 patients); recurrent pulmonary embolism of small vessels of the pulmonary artery with the formation of multiple pulmonary infarctions of different statutes of limitations (1 patient); deep vein thrombosis of the upper extremity (1 patient) (Fig. 8). Thrombotic complications were not diagnosed during life in all patients: ischemic cerebral infarction was diagnosed in life in 3 patients on the basis of relevant clinical symptoms, transmural myocardial infarction – in 2 patients by electrocardiographic changes and elevated serum troponin I. Pulmonary embolism has not been diagnosed in a lifetime (Fig. 2).

Discussion

In the first publications of Chinese researchers, male gender and older age of patients with COVID-19 were identified as risk factors for adverse disease [13]. It was demonstrated that among patients in need of intensive care, death was observed mainly in patients older than 60 years. Each increase in age by 10 years was associ-
ated with a 58% additional risk of adverse effects [14]. According to our data, 75.6% of deaths due to COVID-19 are elderly and senile. However, the data presented in the literature on the effects of COVID-19 on the sex of the patient, show some contradictions. Thus, the authors [14] did not find differences in the survival of patients with severe COVID-19 depending on gender, but other researchers [15] showed a predominance of male patients (67%) among those who died. According to the results of our study, men significantly predominated among those who died as a result of COVID-19 (73.2%). It is assumed that one of the explanations for the higher percentage of severe COVID-19 and, accordingly, lethal outcome in men is a more pronounced expression of ACE2 than in women, but this statement still needs further study [16].

It is believed that the most common pathological sign in lethal cases of COVID-19 is diffuse alveolar damage [11,12]. In COVID-19, the acute stage is characterized by the presence of “hyaline membranes”, and the phase of organization – varying degrees of fibroblasts and myofibroblasts proliferation [11,12]. Signs of diffuse alveolar damage have been described even in the absence of pulmonary ventilation, which was an additional confirmation of the viral nature of the changes found, excluding the effects of ventilation and oxygen [11,17]. Pathomorphological manifestations of diffuse alveolar damage in COVID-19 in 8 of 12 correspond to early acute respiratory distress syndrome [10]. The predominant findings are protein-enriched interstitial edema, “hyaline membranes”, activated pneumocytes, microvascular thromboembolism, blood stasis in capillaries [10], as well as the presence of inflammation signs with lymphocytic infiltration [17].

Alveolar septa are unevenly diluted due to infiltrates of varying severity. They consist mainly of CD4+ and CD8+ T lymphocytes [11,17].

According to the results of our study, the early and dominant in the subsequent course of COVID-19 signs of lung damage in all deaths due to COVID-19 were significant interstitial-alveolar pulmonary edema with the presence of erythrocyte stasis and blood clots in microvessels. Bilateral polysegmental subtotal viral pneumonia in 90.2% of deceased patients was manifested by significant edema and thickening of the alveoli walls with their moderate infiltration by lymphocytes, focal peribronchial and perivascular inflammatory polymorphonuclear infiltration, multiple small atelectases and disiectases. In the majority (87.8%) of deaths from COVID-19, the presence of erythrocytes clusters, hemosiderophages and macrophages, squamous alveolar epithelium, as well as metaplasia of a few alveolocytes on the luminal surface of the alveoli (82.9% of deaths) was determined. It was combined with the presence of absolute lymphopenia in the peripheral blood of 75.6% patients. In patients with COVID-19, peripheral blood lymphopenia correlated with lymphocytic infiltration of the lungs. It was found during morphological examination of the lungs in the deceased, as reported by other researchers [14]. In their opinion, this coincides with the pathogenetic mechanism of viral infection.

Zinselring et al. [18] pay attention to the lesions that indicate a direct effect of the COVID-19: desquamation of the ciliated epithelial cells, the appearance of viral inclusions in the cells of the alveolar epithelium [18]. The role of the virus in the formation of these pathomorphological changes confirms the positive result of PCR on RNA SARS-CoV-2 in the study of lung tissue of deceased patients (9 of 12) in the range from 1.2 × 10^6 to 9.0 × 10^6 copies/ml [10]. Under conditions of viral infection, there is a significant cellular immune response. This is evidenced by mononuclear infiltration of lung tissue with the largest number of CD3+ T lymphocytes. Among them, CD2+, CD5+, CD8+ and the formation of small peribronchial clusters (CD20+) by B-lymphocytes are most often detected [18]. According to D. Wichmann et al. [10] epithelial metaplasia occurs at later stages of COVID-19.

The appearance of neutrophils in the lungs in diffuse alveolar damage is explained by the addition of secondary bacterial microflora [11,12]. The addition of secondary bacterial microflora in our study was pathomorphologically confirmed by the development of fibronous-purulent tracheobronchitis and bilateral subtotal fibrous-purulent bronchopneumonia in 4 patients, as well as bilateral fibronous-purulent pleurisy in 3 (7.3%) patients. Big-focal or sublobar pneumofibrosis was detected by us in 35 (85.4%) patients who died on day 22–27 of the disease. Particular attention is drawn to acute kidney damage, despite the fact that the respiratory system is the main target in COVID-19. It can also have a significant impact on the prognosis. Today, data on morphological changes that occur in the kidneys in patients with a critical course of this infection are accumulating. Thus, H. Su et al. [9] analyzed the pathological changes in the kidney tissue of 26 deaths due to the progression of respiratory failure and multiorgan failure syndrome in COVID-19. In 34.6% of patients, there were laboratory signs in vivo of renal impairment in the form of increased serum creatinine and/or proteinuria, which occurred for the first time [9]. Pathomorphological signs of kidney damage according to the results of light microscopy were represented by diffuse damage to the proximal tubules with loss of border and even foci of necrosis. According to the results of electron microscopic examination, the researchers found accumulations of coronavirus-like particles in the tubular epithelium and in the podocytes of the glomeruli. The main targets for SARS-CoV-2 are tubular and glomerular visceral renal epithelial cells [9]. According to the results of our study, a lifetime increasing in creatinine levels in most patients (75.6%) with a critical course of the disease was found. It revealed the pathomorphological examination in COVID-19 patients: acute tubular necrosis signs (73.2%), focal leukocyte infiltration (12.2%) and microthrombosis (17.1%). Literature data suggest that renal cells absorb factors including systemic hypoxia, abnormal coagulation, and possibly rhabdomyolysis, which is associated with drug or hyperventilation [9]. Also immune inflammation was found. It was confirmed by immunohistochemical infiltration of T-lymphocytes (CD3+, CD8+) tissues of many organs, including the intestines, kidneys, adrenal glands [18].

In the modern literature in many studies, the authors draw attention to the significant frequency of thrombotic complications that occur in severe and critical course of COVID-19, and the complexity of their lifelong diagnosis [10,17]. This feature in COVID-19 is explained by the high
expression of ACE2 in the vascular endothelium. This to some extent explains both the presence of multiorgan lesions and the high risk of thrombosis [6]. The study of pathomorphological signs of thrombosis in patients with COVID-19 allowed researchers to use the term “pulmonary vasculopathy” [19,20]. Autopsy revealed deep vein thrombosis in 58 % of patients in whom venous thromboembolism was not suspected in life [10]. Pulmonary artery thromboembolism was the direct cause of death in one in three deaths due to COVID-19, while microthrombi were regularly detected in small arteries [10].

In our study, more than one in five deaths (22.0 %) due to COVID-19 was pathomorphologically diagnosed with signs of thrombotic complications, the presence of which in almost half of the cases was not established during life. Other researchers report the absence of clinical symptoms of thrombotic complications, including pulmonary embolism [11]. Researchers report clear macroscopic signs of pulmonary embolism in a pathoanatomical study in one of three deaths due to COVID-19 [11]. In addition, researchers have documented several cases not only of pulmonary embolism but also of prostate vein thrombosis, the presence of blood clots in the glomerular capillaries of the kidneys and alveolar capillaries [11].

When analyzing the results of pathomorphological changes, one should pay attention to the high frequency of morphological features in different organs. These changes indicate the presence of chronic comorbidities and a slightly lower level of lifelong diagnosis of these conditions. The vast majority of deaths due to COVID-19 had morphological signs of chronic cardiovascular pathology in the form of diffuse interstitial cardiocclerosis (90.2 %), big-focal postinfarction cardiocclerosis (7.3 %), atherosclerosis of coronary arteries with 50–75 % stenosis (87.8 %), myocardial hypertrophy (78.0 %), focal arterioplenosclerosis (61.0 %). It should be noted that lifelong coronary heart disease was diagnosed in 80.5 % and hypertension in 75.6 % of patients. Literature data also indicate that pre-existing chronic diseases can be identified in all deaths due to COVID-19 [10] with a predominance of the cardiovascular system chronic pathology in most cases, including high-grade coronary artery sclerosis; myocardial scarring, which indicates coronary heart disease, and congestive cardiomyopathy [10]. In the study [17], authors reported the detection of myocardial hypertrophy signs, atherosclerosis of the coronary artery with microscopic acute ischemia signs. Our previous studies on the prognostic role of comorbid pathology in COVID-19 demonstrated a statistically significant effect of the presence of chronic cardiovascular pathology and chronic kidney disease [21].

**Conclusions**

1. The lethal outcome of COVID-19 disease was recorded at day 22.0 [16.0; 27.0] of the disease. Among the dead, there is high percentage of early old age and middle old age patients (75.6 %), men (73.2 %), patients with comorbid pathology (92.7 %).

2. Early lung damage with COVID-19 in the deceased was determined by pronounced interstitial and interstitial-alveolar edema, the presence of erythrocyte stasis, blood clots and hypoperfusion leukocyte stasis in the pulmonary microvessels, as well as the presence in the alveoli of erythrocytes.

3. Bilateral polysegmental subtotal viral pneumonia in 90.2 % of dead patients was characterized by significant edema and thickening of the alveolar walls with their moderate infiltration by lymphocytes, focal peribronchial and perivascular inflammatory polymorphonuclear infiltration, multiple and small exfoliated alveolar epithelium (87.8 %), as well as metaplasia of a few alveolocytes preserved on the luminal surface of the alveoli (82.9 %).

4. One of ten deaths from COVID-19 showed signs of secondary bacterial microflora in the form of fibrous-purulent tracheobronchitis and bilateral subtotal fibrous-purulent bronchopneumonia, as well as bilateral fibrous-purulent pleurisy (7.3 %) and sepsis. In 85.4 % of patients who died on day 22–27 of the disease focal or sublobar pneumofibrosis is determined.

5. In those who died as a result of COVID-19, multiorgan failure is characterized by focal necrosis of the renal tubular epithelium (73.2 %), focal lymphocytic-leukocyte infiltration (12.2 %) and renal microvascular thrombosis (17.1 %), focal centrolobular necrosis 90.2 % and focal lymphocytic-leukocyte infiltration of lobes (7.3 %) of the liver. Lifetime laboratory signs of renal failure were found in 75.6 % of patients, and hepatic failure – in 68.3 % of patients.

6. Pathomorphologically confirmed thrombotic complications occurred in 22.0 % of deceased patients: ischemic cerebral infarction (4 patients); transmural myocardial infarction (1 patient); myocardial infarction complicated by focal infarction pneumonia due to pulmonary embolism of pulmonary artery small vessels (2 patients); recurrent pulmonary embolism of pulmonary artery small vessels with the formation of multiple pulmonary infarctions of different ages (1 patient); deep vein thrombosis of the upper extremity (1 patient).

7. Morphological signs of chronic coronary heart disease and hypertension were identified in most deaths due to COVID-19: atherosclerosis and 50–75 % coronary artery stenosis (87.8 %), diffuse interstitial cardiocclerosis (90.2 %), focal postinfarction cardiomyocardial infarction (7.3 %), myocardial hypertrophy (78.0 %), focal arterioplenosclerosis (61.0 %). At the same time during the life of patients ischemic heart disease was diagnosed in 80.5 % of cases, hypertension – in 75.6 % of cases.

**Conflicts of interest:** authors have no conflict of interest to declare. 

Конфлікт інтересів: відсутні.

**Information about authors:**

Riabokon O. V., MD, PhD, Dsc, Professor, Head of the Department of Infectious Diseases, Zaporizhzhia State Medical University, Ukraine. 

ORCID ID: 0000-0002-7394-4649

Tumanska L. M., MD, PhD, Associate Professor of the Department of Pathological Anatomy and Forensic Medicine, Zaporizhzhia State Medical University, Ukraine.
References

[1] Siddigi, H. K., & Mehran, M. R. (2020). COVID-19 illness in native and immunosuppressed states: A clinical-treatment staging proposal. The Journal of heart and lung transplantation, 39(6), 405-407. https://doi.org/10.1016/j.healun.2020.03.012

[2] Liu, Q., Wang, R. S., Qu, G. Q., Wang, Y. Y., Liu, P., Zhu, Y. Z., Fei, G., Ren, L., Zhou, Y. W., & Liu, L. (2020). Gross examination report of a COVID-19 death autopsy. Fa xue za zhi, 36(1), 21-23. https://doi.org/10.12116/jissn.1004-5619.2020.01.005

[3] Turner, A. J., Hiscott, J. A., & Hooper, N. M. (2004). ACE2: from vaso- peptidase to SARS virus receptor. Trends in pharmacological sciences, 26(9), 450-454. https://doi.org/10.1016/j.tips.2004.08.015

[4] Li, W., Moore, M. J., Wawia, N., Sui, J., Wong, S. K. W., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., Choe, H., & Farzan, M. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426(6965), 490-494. https://doi.org/10.1038/nature02145

[5] Yang, J. K., Lin, S. S., Ji, X. J., & Guo, L. M. (2010). Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta diabetologica, 47(3), 193-199. https://doi.org/10.1007/s12558-009-0192-4

[6] Hoffmann, M., Kleine-Winter, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052

[7] Tay, M. Z., Poh, C. M., Réria, L., MacArty, P. A., & Ng, L. (2020). The virality of COVID-19: immunity, inflammation and intervention. Nature reviews. Immunology, 20(6), 363-374. https://doi.org/10.1038/s41577-020-0311-8

[8] Cominos, J. M., & Levy, J. H. (2020). Thromboinflammation and the hypercoagulability of COVID-19. Journal of thrombosis and haemostasis, 18(7), 1559-1561. https://doi.org/10.1111/jth.14849

[9] Su, H., Yang, M., Wan, C., Li, X., Tang, F., Zhu, H., Y. I., Yang, H. C., Fogo, A. B., Nie, X., & Zhang, C. (2020). Renal Histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international, 98(1), 219-227. https://doi.org/10.1016/j.kint.2020.04.003

[10] Wichmann, D., Sperhake, J. P., Lüdtkehalmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Muthumbha, H., Kniep, I., Schröder, A. S., Burdelski, C., de Heer, G., Niemhaus, A., Frings, D., Pfeiffer, S., Becker, H., Brederede-Wiedling, H., de Weerth, A., Paschen, H. R., Shiktazadeh-Eggers, S., Kluge, S. (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Annals of internal medicine, 173(4), 288-277. https://doi.org/10.1016/j.ajcp.2020.02.002

[11] Menter, T., Hasbauer, D. J., Neinhold, R., Savic, S., Hopfer, H., Deigen- desch, N., Frank, S., Turek, D., Will, N., Pagger, H., Bassetti, S., Leup- pi, J. D., Calthomas, G., Tohaya, M., Mertz, K. D., & Trzakova, A. (2020). Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopatho- logy, 77(2), 198-209. https://doi.org/10.1111/hpa.14134

[12] Tian, S., Xiong, Y., Liu, H., Niu, L., Guo, J., Liao, M., & Xiao, S. Y. (2020). Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern pathology, Inc, 33(6), 1007-1014. https://doi.org/10.1038/s41379-020-0636-z

[13] Wu, Z., & McGoogan, J. M. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 323(13), 1299-1324. https://doi.org/10.1001/jama.2020.2648

[14] Wang, Y., Lu, X., Li, Y., Chen, H., Chen, T., Su, N., Huang, F., Zhou, J., Zhang, B., Yan, F., & Wang, J. (2020). Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. American journal of respiratory and critical care medicine, 201(11), 1430-1436. https://doi.org/10.1016/j.jrsm.2020.03.076L

[15] Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S., & Shang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet. Respiratory medicine, 8(9), 475-481. https://doi.org/10.1016/s2213-2600(20)30079-y

[16] Dasnaha, P., Wong, J. L., Lim, L. M., Li, S., Cho, D., Choo, M., & Su, L. L. (2020). Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. American journal of obstetrics and gynecology, 222(6), 521-531. https://doi.org/10.1016/j.ajo.2020.03.021

[17] Barton, L. M., Duval, E. J., Strober, E., Ghosh, S., Mukhopad- hyay, S. (2020). COVID-19 Autopsies, Oklahoma, USA. American journal of Clinical Pathology, 153(6), 725-733. https://doi.org/10.1093/ajcp/aqaa062

[18] Zinserging, V. A., Vashikova, M. A., Vasiyleva, M. V., Isakov, A. N., Lugovskaya, N. A., Narkevich, T. A., Sukhanova, Yu. V., Semenco- va, N. Yu., & Gusev, D. A. (2020). Voprosy yamotormorenogeneza novoi koronavirusnoi infektii – COVID-19 (Issues of pathology of a new coronavirus infection COVID-19). Jurnal Infektiologii, 122(2), 5-11. https://doi. org/10.22652/jir-2020-12-2-5-11

[19] Griffin, D. O., Jensen, A., Khan, M. C., Chini, J., Chini, K., Saad, J., Parnell, R., Awwad, C., Patel, D. (2020). Pulmonary Embolism and Increased Levels of D-Dimer in Patients with Coronavirus Disease. Emerging infectious diseases, 26(8), 1941-1943. https://doi. org/10.3201/eid2608.201477

[20] Lodigiani, C., Iapichino, G., Carozzo, L., Cecconi, M., Ferracci, P., Sebastiani, T., Kucher, N., Studd, J. D., Sacco, C., Bertuzzi, A., San- dri, M. T., Barco, S., & Humansitas COVID-19 Task Force (2020). Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis research, 191, 9-14. https://doi.org/10.1016/j.thromres.2020.04.024

[21] Riabokon, O. V., Cherkaskyi, V. V., Onishchenko, T. Ye., Riabokon, Yu. Yu. (2021). Features of comorbid pathophysiology and age structure of oxygen-dependent patients with severe coronavirus disease 2019 (COVID-19) depending on outcomes of the disease. Zarozhynyy medical journal, 23(2), 214-219. https://doi.org/10.14739/2310-1210.2021.2.228712